EMZOLAM
Main information
- Trade name:
- EMZOLAM 5 CAP
- Active ingredient:
- TEMOZOLOMIDE
- Available from:
- MIRACALUS
- Dosage:
- 20MG
- Pharmaceutical form:
- CAP
- Composition:
- 5
- Medicine domain:
- Humans
- Medicine type:
- Allopathic drug
Documents
- for the general public:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- for healthcare professionals:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for healthcare professionals.
Localization
- Available in:
-
India
- Language:
- English
Other information
Status
- Source:
- Central Drugs Standard Control Organization
- Last update:
- 09-08-2016
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- Access to this document is only available to registered users.
Register now for full access
25-8-2017
Human medicines European public assessment report (EPAR): Temomedac, temozolomide, Revision: 10, Authorised
Europe - EMA - European Medicines Agency
22-8-2017
Human medicines European public assessment report (EPAR): Temozolomide Sun, temozolomide, Revision: 10, Authorised
Europe - EMA - European Medicines Agency
14-8-2017
Human medicines European public assessment report (EPAR): Temozolomide Hexal, temozolomide, Revision: 13, Authorised
Europe - EMA - European Medicines Agency
8-8-2017
Human medicines European public assessment report (EPAR): Temozolomide Teva, temozolomide, Revision: 16, Authorised
Europe - EMA - European Medicines Agency
7-8-2017
Human medicines European public assessment report (EPAR): Temozolomide Accord, temozolomide, Revision: 15, Authorised
Europe - EMA - European Medicines Agency
4-8-2017
Human medicines European public assessment report (EPAR): Temozolomide Sandoz, temozolomide, Revision: 14, Authorised
Europe - EMA - European Medicines Agency
27-7-2017
Human medicines European public assessment report (EPAR): Temodal, temozolomide, Revision: 29, Authorised
Europe - EMA - European Medicines Agency
20-2-2018
![TEMOZOLOMIDE Capsule [Amneal Pharmaceuticals LLC]](/web/assets/global/img/flags/us.png)
TEMOZOLOMIDE Capsule [Amneal Pharmaceuticals LLC]
Updated Date: Feb 20, 2018 EST
US - DailyMed
21-11-2017
TEMOZOLOMIDE Capsule [Teva Pharmaceuticals USA, Inc.]
Updated Date: Nov 21, 2017 EST
US - DailyMed
1-11-2017
TEMOZOLOMIDE (Temozolomide) Capsule [Chemi Pharma LLC]
Updated Date: Nov 1, 2017 EST
US - DailyMed
26-10-2017
TEMOZOLOMIDE Capsule [Zydus Pharmaceuticals (USA) Inc.]
Updated Date: Oct 26, 2017 EST
US - DailyMed
26-10-2017
TEMOZOLOMIDE Capsule [Cadila Healthcare Limited]
Updated Date: Oct 26, 2017 EST
US - DailyMed
19-10-2017
TEMODAR (Temozolomide) Capsule TEMODAR (Temozolomide) Injection, Powder, Lyophilized, For Solution [Merck Sharp Dohme Corp.]
Updated Date: Oct 19, 2017 EST
US - DailyMed
24-5-2017
Temozolomide Accord (Accord Healthcare Limited)
Temozolomide Accord (Active substance: temozolomide) - Centralised - Yearly update - Commission Decision (2017)3652 of Wed, 24 May 2017
Europe -DG Health and Food Safety
3-5-2017
Temozolomide Teva (Teva B.V.)
Temozolomide Teva (Active substance: temozolomide) - Centralised - Yearly update - Commission Decision (2017) 2982 of Wed, 03 May 2017
Europe -DG Health and Food Safety